Insider trade

Lisata Therapeutics (LSTA): Officer received 15K shares

James Nisco, Officer at Lisata Therapeutics, reported a grant / award of 15K shares.

15K
Shares
Traded
Jan 9, 2026
Filed
Jan 13, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

    What came next

    1. Jan 20, 2026Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
    2. Feb 27, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
    3. Mar 6, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors
    4. May 3, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
    View the official recordSEC Form 4

    How to read SEC Form 4

    Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

    Full guide: What is an SEC Form 4?

    What else is on file for Lisata Therapeutics

    OQRO holds no insider, Congress, fund or contract record for Lisata Therapeutics dated in the last 90 days.

    These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LSTA page.

    How this filing works

    Explore the data

    This is one filing. OQRO holds the rest

    Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

    OQRO is free for everyone. No card, no trial

    OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data